PMID- 25467702
OWN - NLM
STAT- MEDLINE
DCOM- 20150526
LR  - 20220330
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 225
IP  - 1-2
DP  - 2015 Jan 30
TI  - Ketamine and other potential glutamate antidepressants.
PG  - 1-13
LID - S0165-1781(14)00861-0 [pii]
LID - 10.1016/j.psychres.2014.10.028 [doi]
AB  - The need for rapid acting antidepressants is widely recognised. There has been 
      much interest in glutamate mechanisms in major depressive disorder (MDD) as a 
      promising target for the development of new antidepressants. A single intravenous 
      infusion of ketamine, a N-methyl-d-aspartate (NMDA) receptor antagonist 
      anaesthetic agent, can alleviate depressive symptoms in patients within hours of 
      administration. The mechanism of action appears to be in part through glutamate 
      release onto non-NMDA receptors including 
      alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and metabotropic 
      receptors. However these are also reported effects on 5-HT, dopamine and 
      intracellular effects on the mammalian target of rapamycin (mTOR) pathway. The 
      effects of SSRI (Selective Serotonin Reuptake Inhibitor) antidepressants may also 
      involve alterations in NMDA function. The article reviews the effect of current 
      antidepressants on NMDA and examines the efficacy and mechanism of ketamine. 
      Response to ketamine is also discussed and comparison with other glutamate drugs 
      including lamotrigine, amantadine, riluzole, memantine, traxoprodil, GLYX-13, 
      MK-0657, RO4917523, AZD2066 and Coluracetam. Future studies need to link the 
      rapid antidepressant effects seen with ketamine to inflammatory theories in MDD.
CI  - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved.
FAU - Dutta, Arpan
AU  - Dutta A
AD  - Neuroscience & Psychiatry Unit, Institute of Brain, Behaviour and Mental Health, 
      Stopford Building, University of Manchester, Manchester M13 9PT, UK. Electronic 
      address: arpan.dutta@postgrad.manchester.ac.uk.
FAU - McKie, Shane
AU  - McKie S
AD  - Neuroscience & Psychiatry Unit, Institute of Brain, Behaviour and Mental Health, 
      Stopford Building, University of Manchester, Manchester M13 9PT, UK.
FAU - Deakin, J F William
AU  - Deakin JFW
AD  - Neuroscience & Psychiatry Unit, Institute of Brain, Behaviour and Mental Health, 
      Stopford Building, University of Manchester, Manchester M13 9PT, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141113
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
RN  - 0 (Antidepressive Agents)
RN  - 0 (Receptors, AMPA)
RN  - 0 (Receptors, Metabotropic Glutamate)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - 690G0D6V8H (Ketamine)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Glutamic Acid/*metabolism
MH  - Humans
MH  - Ketamine/pharmacology/*therapeutic use
MH  - Memantine/therapeutic use
MH  - Receptors, AMPA/drug effects
MH  - Receptors, Metabotropic Glutamate/drug effects
MH  - Receptors, N-Methyl-D-Aspartate/drug effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Glutamate
OT  - Ketamine
OT  - Major depressive disorder
OT  - N-methyl-d-aspartate
OT  - alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
EDAT- 2014/12/04 06:00
MHDA- 2015/05/27 06:00
CRDT- 2014/12/04 06:00
PHST- 2014/04/26 00:00 [received]
PHST- 2014/09/29 00:00 [revised]
PHST- 2014/10/28 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/05/27 06:00 [medline]
AID - S0165-1781(14)00861-0 [pii]
AID - 10.1016/j.psychres.2014.10.028 [doi]
PST - ppublish
SO  - Psychiatry Res. 2015 Jan 30;225(1-2):1-13. doi: 10.1016/j.psychres.2014.10.028. 
      Epub 2014 Nov 13.